Scholarlink

<p>Many patients with metastatic and recurrent colorectal cancer (CRC) have poor outcomes, due to resistance to current treatment approaches. Missense mutations in the <i>TP53</i> gene are found in about 65% of CRCs, but no current treatment approach targets mutant <i>TP53</i> activity. To develop a vaccine approach against CRCs expressing a mutant p53 protein, we used a murine CRC model with conditional expression of a <i>Trp53</i> codon R270H missense allele, and immunized mice with the experimental vaccine, which combined a synthetic R270H p53 peptide and wild-type p53 recombinant protein with a mucosal nanoemulsion (NE) adjuvant. The p53/NE vaccine was administered intranasally to the mice after mutant p53 induction and tumor initiation. Vaccinated mice had markedly increased serum anti-p53 IgG, IgG2a, and IgG2b as compared to control mice. The vaccination also enhanced antigen-specific Th1 and Th17 cellular immune responses, as shown by increasing production of IFNγ, IL-17a and IL-2. The immunized animals had significantly decreased tumor size, prolonged survival and increased tumor CD8<sup>+</sup> T cell infiltrates. Collectively, we have demonstrated a mucosal vaccine against mutated p53 protein in CRC can induce antigen-specific cellular and humoral immunity. The findings suggest potential value in pursuing mutated p53 as a vaccine target in CRC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A p53 peptide mucosal vaccine induces cellular and humoral immunity and anti-tumor effects in a murine colorectal cancer model

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月25日

查看全文
  • Su He Wang,
  • Zhengyi Cao,
  • Katarzyna W. Janczak,
  • Ying Feng,
  • Maranne Green,
  • Shengzhuang Tang,
  • Eric R. Fearon,
  • James R. Baker Jr

摘要

Many patients with metastatic and recurrent colorectal cancer (CRC) have poor outcomes, due to resistance to current treatment approaches. Missense mutations in the TP53 gene are found in about 65% of CRCs, but no current treatment approach targets mutant TP53 activity. To develop a vaccine approach against CRCs expressing a mutant p53 protein, we used a murine CRC model with conditional expression of a Trp53 codon R270H missense allele, and immunized mice with the experimental vaccine, which combined a synthetic R270H p53 peptide and wild-type p53 recombinant protein with a mucosal nanoemulsion (NE) adjuvant. The p53/NE vaccine was administered intranasally to the mice after mutant p53 induction and tumor initiation. Vaccinated mice had markedly increased serum anti-p53 IgG, IgG2a, and IgG2b as compared to control mice. The vaccination also enhanced antigen-specific Th1 and Th17 cellular immune responses, as shown by increasing production of IFNγ, IL-17a and IL-2. The immunized animals had significantly decreased tumor size, prolonged survival and increased tumor CD8+ T cell infiltrates. Collectively, we have demonstrated a mucosal vaccine against mutated p53 protein in CRC can induce antigen-specific cellular and humoral immunity. The findings suggest potential value in pursuing mutated p53 as a vaccine target in CRC.